Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
December 16th, 2025
Clinuvel Pharmaceuticals to File ACTH Generic for Approval in 2026 for Billion Dollar Market
Read More
December 16th, 2025
Clever Culture Systems - Positioned for Strong Growth and Profitability
Read More
December 16th, 2025
Syntara's Clever Phase Ib Skin Scarring Study in 2026 to Address 'Enormous' Market Opportunity
Read More
December 16th, 2025
Imugene Gets Clear Direction from FDA to Move into Pivotal Study
Read More
December 16th, 2025
Actinogen Medical - Good Rational for Positive Trial Outcome in 2026
Read More
November 21st, 2025
Chimeric Therapeutics - Stable Disease in Cohort 2
Read More
November 21st, 2025
Imugene Prioritises Azer-Cel Program; Reduces Internal Drug Development
Read More
October 28th, 2025
Aroa Biosurgery Delivers 4th Consecutive Positive Cashflow Quarter
Read More
October 28th, 2025
Second Best Quarter of Sales for Cogstate
Read More
October 28th, 2025
Robust Results for Blinklab Paves Way for Registrational Autism Study
Read More
October 13th, 2025
Clinical Trial Progress: Imugene Data Continues to Impress
Read More
October 12th, 2025
Positive Outcome for Dimerix from PARASOLProject Sets Up FDA Meeting
Read More
October 11th, 2025
Amplia Achieves Additional Partial Response as Data Begins to Mature
Read More
October 10th, 2025
Chimeric Therapeutics - More EncouragingData from Phase I Studies
Read More
September 26th, 2025
Clinuvel Pharmaceuticals Gains Extended Use of Scenesse in Europe
Read More
September 26th, 2025
Botanix Pharmaceuticals - Profitability in Sight?
Read More
September 26th, 2025
Chimeric Therapeutics - More Data Emerging from Phase I CAR-T Study
Read More
September 12th, 2025
Aroa Biosurgery — Records Third Positive Cashflow Quarter
Read More
September 11th, 2025
Clinuvel Grows Cash Balance to $224M and Progresses Phase III Vitiligo Program
Read More
August 26th, 2025
Actinogen Medical — Why Xanamem Should Deliver Positive Results in Phase IIb Alzheimer’s Disease Study
Read More
Pages
1
2
3
4
5
6
7
8
9
10
